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Abstract
Background: We conducted a systematic review and meta-analysis to assess efficacy and safety of prophylactic
HPV vaccines against cervical cancer precursor events in women.
Methods: Randomized-controlled trials of HPV vaccines were identified from MEDLINE, Cochrane Central Register
of Controlled Trials, conference abstracts and references of identified studies, and assessed by two independent
reviewers. Efficacy data were synthesized using fixed-effect models, and evaluated for heterogeneity using I
2
statistic.
Results: Seven unique trials enrolling 44,142 females were included. The fixed-effect Relative Risk (RR) and 95%
confidence intervals were 0.04 (0.01-0.11) and 0.10 (0.03-0.38) for HPV-16 and HPV 18-related CIN2+ in the per-
protocol populations (PPP). The corresponding RR was 0.47 (0.36-0.61) and 0.16 (0.08-0.34) in the intention-to-treat
populations (ITT). Efficacy against CIN1+ was similar in scale in favor of vaccine. Overall vaccines were highly
efficacious against 6-month persistent infection with HPV 16 and 18, both in the PPP cohort (RR: 0.06 [0.04-0.09]
and 0.05 [0.03-0.09], respectively), and the ITT cohorts (RR: 0.15 [0.10-0.23] and 0.24 [0.14-0.42], respectively). There
was limited prophylactic effect against CIN2+ and 6-month persistent infections associated with non-vaccine
oncogenic HPV types. The risk of serious adverse events (RR: 1.00, 0.91-1.09) or vaccine-related serious adverse
events (RR: 1.82; 0.79-4.20) did not differ significantly between vaccine and control groups. Data on abnormal
pregnancy outcomes were underreported.
Conclusions: Prophylactic HPV vaccines are safe, well tolerated, and highly efficacious in preventing persistent
infections and cervical diseases associated with vaccine-HPV types among young females. However, long-term
efficacy and safety needs to be addressed in future trials.
Background
Oncogenic HPV infection is the necessary cause of cer-
vical cancer [1]. Worldwide 70% of invasive cervical can-
cer cases are caused by Human Papillomavirus (HPV)
16 or 18, with HPV 16 being the most common type,
detected in 55% of cases, followed by HPV 18, in 15% of
cases [2]. Other oncogenic HPV types including 31, 33,
35, 45, 52 and 58 that are phylogenetically related to
HPV 16 and 18 account for an additional 18% of all
cases. Results from randomized controlled trials (RCTs)
of prophylactic HPV vaccines have shown consistently
high efficacy in preventing infection and subsequent
precancerous cervical lesions associated with vaccine-
type oncogenic HPV (HPV 16 and 18) as well as phylo-
genetically-related oncogenic HPV types. However, due
to variability in populations studied, vaccine composi-
tion, and efficacy populations defined in different ana-
lyses, understanding the published results can prove to
be challenging. There is also a need in public at large,
including families of targeted women and health care
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decisions.
Two meta-analyses have been published evaluating pro-
phylactic L1 VLP-based HPV vaccine efficacy and safety
[3,4]. Few reports have also presented similar data from
individual RCTs [5,6]. However, these studies had limita-
tions in addressing multiple clinical endpoints assessed in
RCTs [3], and different virus-like-particle (VLP) composi-
tions of individual vaccines [4]. In addition, since the pub-
lication of the aforementioned meta-analyses [3,4], newer
RCTs with reports on cross-protection have been pub-
lished. The present study aims to provide a comprehensive
assessment of vaccine safety and efficacy against multiple
virological and clinical endpoints using the techniques of
systematic review and meta-analysis.
Methods
Identification and Eligibility of Relevant Studies
A systematic search of MEDLINE, Cochrane Library and
the Cochrane Central Register of Controlled Trials was
conducted to identify reports of RCTs of prophylactic
HPV vaccines published up to July 31
st, 2009, using a
combination of index terms: “Human Papillomavirus”,
“Papillomavirus vaccines”, “Randomized controlled
trials”,a n d“Controlled clinical trials”. Additional rele-
vant studies were sought through hand search of confer-
ence abstract books from IPVS (International
Papillomavirus Society) from 2006 to 2009, and biblio-
graphies of obtained studies.
Inclusion and Exclusion Criteria
RCTs published in English of L1 VLP-based HPV vac-
cines that were conducted among women and presented
measurement of prophylactic efficacy against HPV infec-
tion or diseases of interest were included. Trials report-
ing male vaccination or therapeutic vaccination were
excluded. Additionally, we excluded ad hoc subgroup
analyses of existing RCTs or combined analyses of mul-
tiple RCTs. In the case a RCT reported both interim
and final analyses, data from final analyses with com-
plete follow-up were used.
Outcomes
High-grade cervical lesions or worse (CIN2+), including
Cervical Intraepithelial Neoplasia (CIN) grade 2-3, Ade-
nocarcinoma in Situ (AIS), and cervical carcinoma, was
the recommended endpoint for establishing efficacy of
prophylactic HPV vaccines by WHO and consistently
reported in most trials. It was, therefore, chosen as the
primary endpoint for efficacy in this review. As persistent
HPV infection is an obligate precursor of CIN2-3 and
cervical cancer [7], type-specific persistent infections was
chosen as the secondary endpoint for efficacy. Further-
more, management of cervical dysplasia of any grade is
associated with substantial health care cost in developed
countries. Efficacy estimates for CIN 1 or worse (CIN1+)
can provide insight for potential impact of vaccination on
health care cost. CIN1+ was hence also evaluated as the
secondary endpoint. In addition, we examined occur-
rence of adverse events (AE) and vaccine-related adverse
events for assessment of vaccine safety.
Data Extraction
Data were extracted by two independent reviewers (BL
and AK) using a standardized data extraction form. Any
discrepancies were resolved by consensus or in consulta-
tion with a third reviewer. We extracted detailed infor-
mation on trial design, inclusion/exclusion criteria,
participant characteristics, vaccine and placebo adminis-
tered, trial endpoints, efficacy populations, and metho-
dological quality from all included trials.
Statistical Analysis
Effect sizes were summarized as Risk Ratios (RRs) and
associated 95 percent confidence intervals. A RR less
than one suggested vaccine protection against a specific
virological or clinical endpoint. Consistent with defini-
tions used in vaccine RCTs, efficacy was estimated as
[1-RR] and expressed as percentage. Three types of
populations were defined for efficacy analyses: The
intention-to-treat population (ITT), the modified inten-
tion-to-treat population (MITT), and the per-protocol
population (PPP). Vaccine efficacy was assessed in ITT
and PPP cohorts respectively. Efficacy estimates from
MITT cohorts were used in the absence of ITT esti-
mates. Vaccine safety was primarily evaluated in ITT
cohorts among women who received at least one injec-
tion of vaccine or control and had available follow-up,
except in one trial [8,9]. A fixed effect model was
applied to obtain pooled estimates of vaccine efficacy
and safety. Heterogeneity between studies was assessed
using the Cochrane’sQa n dI
2 statistics [10]. Sensitivity
analyses according to key methodological quality
domains and study characteristics were planned a priori
to explore possible sources of heterogeneity as well as to
assess the robustness of the observed results. The possi-
bility of publication bias was assessed using the Begg
and Egger funnel plot method [11,12]. The systematic
review was performed according to the standards
recommended by Cochrane Collaboration [13]. All ana-
lyses were performed in RevMan statistical software [14]
following the PRISMA guidelines [15].
Results
I. Selection of Studies
Study identification and selection was demonstrated in
the flow diagram in Figure 1. Of 579 publications identi-
fied through an initial search of databases and
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borated in Figure 1. In total, thirteen publications repre-
senting seven unique RCTs met the eligibility criteria
and were included in the current review.
II. Characteristics of Included Trials and Trial Participants
Characteristics of RCTs included in the current review
are summarized in Table 1. Unique trials were identified
by first authors of associated publication(s). The major-
ity of trials were multinational trials. Eligible participants
were non-pregnant women aged 15 to 44 who had 6 or
fewer lifetime sexual partners at enrollment and had no
history of abnormal Pap smears. Three prophylactic vac-
cines were evaluated in the seven trials: The bivalent
vaccine (containing HPV 16 and 18 VLPs) from GlaxoS-
mithKline in two trials; the monovalent (containing
HPV 16 VLPs) and quadrivalent vaccine (containing
HPV 6, 11, 16 and 18 VLPs) from Merck in one and
four trials, respectively. Uniform to all trials, vaccines or
controls were administered in a three-dose regimen
within a 6-month time frame. Proprietary adjuvant was
used with each type of vaccine to enhance immunogeni-
city. All trials used placebo as the comparator except for
two in which all or part of the control group received
hepatitis A vaccine [16], or placebo plus hepatitis B
vaccine [17]. Participants were tested for DNA evidence
of HPV infection every 6 months and for cytological
abnormality every 6 or 12 months. The length of trials
ranged from 26 to 60 months.
The mean age of participants for the majority of trials
was approximately 20 years except in the trial of Munoz
and associates where older females were recruited
(mean age 34) (Table 2) [18]. The majority of partici-
pants in individual trials had two or fewer lifetime sex-
ual partners and used hormonal contraceptives.
Approximately 90% of participants in each trial had nor-
mal cytology at enrollment.
Methodological quality was generally high for included
trials. All trials demonstrated adequate reporting for
allocation concealment, blinding, and drop-outs or loss-
to-follow-up. Expected efficacy and sample size esti-
mates were presented for each trial with considerations
for dropout or loss-to-follow-up.
The Begg and Egger funnel plot (Additional file 1) for
the primary endpoint, CIN2+ associated with HPV 16/
18 in the ITT cohorts (p = 0.602), indicated no signifi-
cant publication bias.
III. Outcomes
1) CIN2+ associated with HPV 16 (Figure 2A)
The pooled RR for 4 RCTs enrolling 28,639 participants
was 0.47 (95% CI: 0.36-0.61) in ITT cohorts, corre-
sponding to a pooled efficacy of 53% and indicating a
statistically significant benefit with vaccine use. How-
ever, there was significant heterogeneity among pooled
studies (Cochrane’s Q, p < 0.001; I
2 = 87%).
Comparable efficacy estimates were reported by PPP
cohort of individual trials. The pooled RR for PPP
cohorts (3 RCTs, 22,940 participants) was 0.04 (95% CI:
0.01-0.11), showing a statistically significant reduction of
96% in CIN2+ incidence due to vaccination.
2) CIN2+ associated with HPV 18 (Figure 2B)
Analysis using ITT cohorts showed a statistically signifi-
cant benefit of vaccination with a pooled RR (3 RCTs,
28,053 participants) of 0.16 (95% CI: 0.08-0.34), translat-
ing to an 84% protection against HPV 18 associated
CIN2+ for vaccine recipients.
Two of the three trials included in the ITT analyses
provided extractable data for the PPP analyses. The
overall RR for PPP cohorts (2 RCTs, 23,565 participants)
was 0.10 (95% CI: 0.03-0.38), equivalent to a 90% pro-
tection against HPV 18 associated CIN2+ for vaccine
recipients compared with control recipients.
3) CIN1+ associated with HPV 16 (Figure 3A)
Vaccines of different compositions demonstrated a sta-
tistically significant level of protection against HPV 16-
associated CIN 1+ in ITT cohorts. The pooled RR (4
RCTs, 21,891 participants) was 0.43 (95% CI: 0.33-0.58)
corresponding to a 57% reduction in CIN1+ incidence
Figure 1 Inclusion and exclusion of trials in study selection.
RCTs, randomized controlled trials.
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Page 3 of 16Table 1 Characteristics of randomized controlled trials included in the review
Koutsky &
Mao et al[28,29]
Harper
et al [8,9]
Villa
et al [23,30]
FUTURE I
[17,31,32]
FUTURE II
[25,31,32]
PATRICIA
[16,33]
Muñoz
et al [18]
Phase III III II III III III III
No. of study sites 16 32 5 62 90 135 38
Countries included 1 3 5 16 13 14 7
Year of study enrollment 10/1998-11/1999 11/2003-07/2004 Not reported 01/2002-03/2003 06/2002-05/2003 05/2004-06/2005 06/2004-04/2005
Funding source Merck GlaxoSmithKline Merck Merck Merck GlaxoSmithKline Merck
Inclusion Criteria
Age 16-25 15-25 16-23 16-24 15-26 15-25 24-45
Lifetime no. of sexual
partners
≤ 5 ≤ 6 ≤ 4 ≤ 4 ≤ 4 ≤ 6 No restriction
Exclusion Criteria Pregnancy, history of
abnormal Pap smear
History of abnormal
Pap smear, or
ablative or excisional
treatment of cervix;
ongoing treatment
for external
condylomata;
seropositive for HPV
16 or 18; DNA
positive for any of 14
HR HPV in past 90
days
Pregnancy, history of
abnormal Pap smear
Pregnancy, history of
abnormal Pap smear
or genital warts
Pregnancy, history of
abnormal Pap smear
History of
colposcopy,
pregnancy,
breastfeeding,
autoimmune diseases
or immunodeficiency
Pregnancy, history of
genital warts, present
or past cervical
disease,
immunocompromised
Intervention & Comparator
Vaccine component HPV 16 VLPs HPV 16, 18 VLPs HPV 6, 11, 16, 18
VLPs
HPV 6, 11, 16, 18 VLPs HPV 6, 11, 16, 18 VLPs HPV 16, 18 VLPs HPV 6, 11, 16, 18 VLPs
VLP amount (μg) 40 20/20 20/40/40/20 20/40/40/20 20/40/40/20 20/20 20/40/40/20
Vaccine adjuvant 225 μg AAHS AS04 (500 μg/50 μg) 225 μg AAHS 225 μg AAHS 225 μg AAHS AS04 (500 μg/50 μg) 225 μg AAHS
Comparator Placebo Placebo Placebo * Placebo/Placebo
+Hepatitis B vaccine
Placebo Hepatitis A vaccine Placebo
Comparator adjuvant 225 μg AAHS 500 μg aluminium
hydroxide
225 or 450 μg AAHS 225 μg AAHS 225 μg AAHS 500 μg aluminium
hydroxide
225 μg AAHS
Administration schedule month 0, 2, 6 month 0, 1, 6 months 0, 2, 6 month 0, 2, 6 month 0, 2, 6 month 0, 1, 6 month 0, 2, 6
Clinical Protocol
Frequency of HPV DNA test 6 month interval 6 month interval 6 month interval 6 month interval 6 month interval 6 month interval 6 month interval
Frequency of cytology test 6 month interval 6 month interval 6 month interval 6 month interval 12 month interval 12 month interval 6 month interval
Length of trial (months) 41.0 Initial trial: 27 Follow-
up study: 53
Initial trial: 36 Follow-
up study: 60
36.0 (mean) 36.0 (mean) 39.4 (mean) 26.4 (mean)
Endpoints
Primary Persistent HPV 16
infection
Incidence infection
with HPV 16, and/or
18.
Combined incidence
of HPV 6, 11, 16 and/
or 18-associated 6-
month persistent
infection, CIN1-3, AIS,
VIN1-3, VaIN1-3,
external genital warts
and cervical, vulvar
or vaginal cancer.
Incidence of HPV 6, 11,
16, and/or 18-
associated genital
warts, CIN1-3, VIN1-3,
VaIN1-3, AIS, and
cervical, vulvar or
vaginal cancer
HPV 16 and/or 18-
associated CIN 2-3, AIS
and cervical cancer
HPV 16/18-associated
CIN2+
Combined incidence
of 6-month persistent
infection, CIN1-3,
VIN1-3, VaIN1-3, AIS,
cervical, vulvar or
vaginal cancer, and
genital warts
associated with HPV
6, 11, 16 or 18, or
with HPV 16 or 18
alone.
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6Table 1 Characteristics of randomized controlled trials included in the review (Continued)
Secondary Transient or
persistent HPV 16
infection
Persistent infection
with HPV 16, 18 or
16/18; HPV 16/18-
associated LSIL, HSIL,
CIN1-3 and cancer
Combined incidence
of HPV 6, 11, 16 and/
or 18-associated CIN1-
3, AIS and cancer;
Persistent infection,
CIN1-3 and AIS
associated with HPV
31, 33, 45, 52, 58.
Persistent infection,
CIN1-3 and AIS
associated with HPV 31,
33, 45, 52, 58
Persistent infection
with HPV 16, 18 or
other oncogenic
types; HPV 16/18-
associated CIN1+;
immunogenicity and
safety
Combined incidence
of 6-month persistent
infection, CIN1-3,
VIN1-3, VaIN1-3, AIS,
cervical, vulvar or
vaginal cancer, or
genital warts
associated with HPV 6
or 11
Populations for Efficacy Analysis
Per-protocol population (PPP) All subjects that
received 3 doses of
vaccine/placebo;
DNA negative for
HPV 16 in cervical
swab and biopsy
from day 1 to month
7; seronegative for
HPV 16 on day 1;
had no protocol
violation; had a
month 7 visit within
14-72 days after the
third vaccination
All subjects that
received 3 doses of
vaccine/placebo;
DNA negative for 14
HR HPV on day 1;
cytologically negative
and seronegative for
HPV 16 and 18 on
day 1; had no
protocol violation
All subjects that
received 3 doses of
vaccine/placebo
within a year;
seronegative and
DNA negative for
HPV 6, 11, 16 or 18
on day 1; remained
DNA negative for the
same HPV type(s)
through month 7;
had no protocol
violation
All subjects that
received 3 doses of
vaccine/placebo within
a year; seronegative
and DNA negative for
HPV 6, 11, 16 or 18 on
day 1; remained DNA
negative for the same
HPV type(s) through
month 7; had no
protocol violation.†
All subjects that
received 3 doses of
vaccine/placebo within
a year; seronegative
and DNA negative for
H P V1 6o r1 8o nd a y1 ;
remained DNA negative
for the same HPV type
(s) through month 7;
had no protocol
violation.†
All subjects that
received 3 doses of
vaccine/placebo;
seronegative to HPV
16 or 18 on day 1;
DNA negative to HPV
16 or 18 on day1
and month 6; had
normal or low-grade
cytology at baseline,
had no protocol
violation
All subjects that
received 3 doses of
vaccine/placebo
within a year;
seronegative and
DNA negative in
cervicovaginal swab
and/or biopsy
samples for HPV 6,
11, 16 or 18 on day 1;
remained DNA
negative to the same
HPV type(s) through
month 7; had no
protocol violation;
had one or more
follow-up visits after
month 7
Intention-to-treat (ITT)/
Modified Intention-to-treat
(MITT) population
MITT2: All subjects
that received ≥1
dose of vaccine/
placebo.
ITT: All subjects that
received ≥1 dose of
vaccine/placebo;
DNA negative for 14
HR HPV on day 1;
had data available for
outcome
measurement.
MITT: All subjects
that received ≥1
dose of vaccine/
placebo; seronegative
and DNA negative to
HPV 6, 11, 16 or 18
on day 1.
ITT: All subjects that
had undergone
randomization,
regardless of their
baseline HPV status or
evidence of HPV-
associated anogenital
disease.
ITT: All subjects that
had undergone
randomization,
regardless of their
baseline HPV status or
evidence of cervical
neoplasia
ITT: All subjects that
received ≥1 dose of
vaccine/placebo;
DNA negative to HPV
16 or 18 on day 1;
had data available for
outcome
measurement.
ITT: All subjects that
received ≥1 dose of
vaccine/placebo; had
one or more follow-
up visits after day1.
Methodological Quality
Allocation concealment Adequate Adequate Adequate Adequate Adequate Adequate Adequate
Blinding Adequate Adequate Adequate Adequate Adequate Adequate Adequate
Dropout/loss-to-follow-up
reported
Yes Yes Yes Yes Yes Yes Yes
Expected efficacy (1-RR) 0.75 0.70 0.80 0.80 0.80-0.90 0.85 0.80
Sample size calculation
performed
Yes Yes Yes Yes Yes Yes Yes
a = 0.05
(one-sided)
b =
0.10
a = 0.05
(two-sided)
b =
0.20
a = 0.05
(two-sided)
b =
0.10
a = 0.0125
(one-sided)
b =
0.09
a = 0.02055
(one-sided)
b =
0.10
a = 0.05
(two-sided)
b =
0.06
– b = 0.13
HR HPV: High-risk HPV includes HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68; CIN: Cervical intraepithelial neoplasia; AIS: Adenocarcinoma in situ; CIN1+: Cervical intraepithelial neoplasia grade 1 or
worse, including CIN1-3, AIS and cervical cancer. CIN2+: Cervical intraepithelial neoplasia grade 2 or worse, including CIN2-3, AIS and cervical cancer; LSIL: Low-grade intraepithelial lesion; HSIL: High-grade
intraepithelial lesion; VIN: Vulvar intraepithelial neoplasia; VaIN: Vaginal intraepithelial neoplasia. VLPs: Virus-like particles; AAHS: Amorphous aluminium hydroxyphosphate sulphate. AS04: 500 μg aluminum hydroxide
and 50 μg 3-O-desacyl-4’-monophosphoryl lipid A; RR: Risk ratio, the ratio of event rates of vaccine and control group.
* A subset of 466 subjects in the treatment arm received quadrivalent vaccine and Hepatitis B vaccine, and 467 subjects in control arm received placebo and Hepatitis B vaccine.
† Per-protocol population for evaluation of cross-protection included subjects who received ≥1 vaccination and, at enrollment were seronegative and DNA negative for each of vaccine HPV types (6, 11, 16, and 18);
were DNA negative for each of 10 non-vaccine types (31, 33, 35, 39, 45, 51, 52, 56, 58, and 59); and had a normal Pap test result.
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6Table 2 Baseline characteristics of participants in the intention-to-treat cohort of randomized controlled trials included in the review
Characteristics,
n (%)
Koutsky & Mao
et al. §
Harper
et al.
Villa
et al.
FUTURE I FUTURE II PATRICIA Muñoz
et al.
Vaccine
(n =
768)
Control
(n =
765)
Vaccine
(n =
560)
Control
(n =
553)
Vaccine
(n =
277)
Control
(n =
275)
Vaccine
(n =
2723)
Control
(n =
2732)
Vaccine
(n =
6087)
Control
(n =
6080)
Vaccine
(n =
9319)
Control
(n =
9325)
Vaccine
(n =
1911)
Control
(n =
1908)
Age, mean (SD) 20.0 (1.6) 20.1 (1.6) 20.4 (2.8) 20.5 (2.7) 20.2 (1.7) 20.0 (1.7) 20.2 (1.8) 20.3 (1.8) 20.0 (2.2) 19.9 (2.1) 20.0 (3.1) 20 (3.1) 34.3 (6.3) 34.3 (6.3)
HPV 16 Positivity
DNA –––– 49 (17.7)
† 51(18.5)
† 238 (8.9) 227 (8.4) 543 (9.1) 545 (9.1) 516 (5.6) 478 (5.2) ––
Serology 143
(12.0)
166
(13.9)
–– 312 (11.5) 319 (11.7) 652 (10.7) 688 (11.3) 1544 (16.7) 1552 (16.8) ––
HPV 18 Positivity
DNA –––– 17 (6.1)
† 21 (7.6)
† 86 (3.2) 83 (3.1) 230 (3.8) 242 (4.0) 215 (2.3) 216 (2.3) ––
Serology –––– 93 (3.4) 90 (3.3) 227 (3.7) 236 (3.9) 1076 (11.7) 1070 (11.6)
Lifetime no. of sexual
partners
≤ 5 ≤ 6 ≤ 4 ≤ 4 ≤ 4 ≤ 6 No restriction
None 38 (5) 34 (4) 90 (16) 85 (16) 17 (6) 16 (6) –––– 294 (3)
†† 292 (3)
†† 0 (0) 2 (0.1)
One 218 (28) 200 (26) 197 (35) 188 (35) 80 (29) 88 (32) –––– 5862
(63)
††
5869
(63)
††
719 (38) 751 (39)
Two/Two to five 173 (23) 173 (23) 259 (46) 242 (45) 73 (26) 75 (27) –––– 1114
(12)
††
1161
(13)
††
385 (20) 362 (19)
Three/Three or more 138 (18) 131 (17) –– 67 (24) 50 (18) –––– 636 (7)
†† 595 (6)
†† 229 (12) 223 (12)
Four/Four or more 105 (14) 144 (19) –– 40 (14) 46 (17) –––––– 142 (7) 130 (7)
Five/Five or more 96 (13) 83 (11) 14 (3) 18 (3) –––––– 433 (23) 437 (23)
Smoking status
Never smoker –– 102 (18) 85 (16) – ––––– 6401 (69)* 6388 (69)* 923 (48) 935 (49)
Former smoker –– 164 (30) 138 (26) – ––––– 2706 (29)* 2726 (29)* 159 (8) 148 (8)
Current smoker 183 (24) 190 (25) 294 (52) 310 (58) –– 696 (26) 716 (26) –––– 339 (18) 332 (17)
Chlamydia trachomatis
Negative –––––– 2565 (94) 2545 (93) 5723 (94) 5737 (94) 8155 (88) 8188 (88) ––
Positive 24 (3) 19 (3) –––– 118 (4) 135 (5) 258 (4) 224 (4) 478 (5) 475 (5) ––
Contraceptive use
Barrier –––– 63 (23) 76 (28) 872 (32) 874 (32) –––– 441 (23) 425 (22)
Hormonal –––– 161 (58) 157 (57) 1568 (58) 1539 (57) 3613 (60) 3614 (60) 5544 (59) 5662 (61) 596 (31) 591 (31)
Behavioral –––– 48 (17) 48 (17) 487 (18) 498 (18) –––– 165 (9) 184 (10)
Other –––– 21 (8) 17 (6) 125 (5) 138 (5) –––– 748 (39) 749 (39)
Cytological status at entry
Normal 656 (88) 655 (87) –––– 2360 (89) 2326 (88) 5222 (87) 5242 (89) 8395 (90) 8450 (91) ––
Abnormal 84 (11) 96 (13) –––– 288 (11) 316 (12) 697 (12) 654 (11) 908 (10) 860 (10) ––
† Seropositive or DNA positive to HPV 16 or 18 on day 1. †† Reported as “number of sexual partners in past year” in PATRICIA study. § Participant characteristics were presented for the per-protocol population only.
* Never smoker category includes participants who never smoke or smoked for ≤6 months (current/past); Former smoker category includes participants who smoked ≥6 months (current/past) in PATRICIA trial.
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6for vaccine recipients compared with control recipients.
However, there was statistically significant heterogeneity
among included trials (Cochrane’s Q, p = 0.006; I
2 =
76%). The summary RR for PPP cohorts (2 RCTs, 5,240
participants) was 0.02 (95% CI: 0.00-0.11), indicating a
95% reduction in CIN1+ incidence due to vaccine use.
4) CIN1+ associated with HPV 18 (Figure 3B)
HPV vaccine provided a statistically significant protec-
tion against HPV 18-associated CIN1+ for vaccine reci-
pients in ITT cohorts with a pooled RR (3 RCTs, 20,885
participants) of 0.22 (95% CI: 0.10-0.44), translating to
an efficacy of 78%. Only one of three trials provided
Figure 2 Vaccine efficacy against cervical intraepithelial neoplasia grade 2 or worse (CIN2+) associated with HPV 16 and 18
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Page 7 of 16efficacy data for PPP cohort, reporting a RR (1 RCT,
4,222 participants) of 0.03 (95% CI: 0.00-0.51), a 97%
reduction.
5) Persistent HPV 16 infection of ≥6 months (Figure 4A)
Persistent infection of ≥6m o n t h sw a sd e f i n e da st h e
detection of same HPV DNA at two or more consecu-
tive visits over a minimum of 4 months from the
beginning of case counting. While three RCTs reported
efficacy information for PPP cohorts, only two provided
information for ITT cohorts. The pooled RR (2 RCTs,
11,964 participants) for the risk of 6-month persistent
HPV 16 infection in ITT cohorts was 0.15 (95% CI:
0.10-0.23), equivalent to an 85% of risk reduction for
vaccine recipients compared with control recipients.
Figure 3 Vaccine efficacy against cervical intraepithelial neoplasia grade 1 or worse (CIN1+) associated with HPV 16 and 18.
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Page 8 of 16A statistically significant protection derived from vac-
cine use was observed in PPP cohorts. The pooled RR
(3 RCTs, 14,485 participants) was 0.06 (95% CI: 0.04-
0.09), corresponding to a 94% lower risk of persistent
HPV 16 infection for vaccine recipients in PPP cohorts.
6) Persistent HPV 18 infection of ≥6 months (Figure 4B)
Vaccines conferred a statistically significant protection
against 6-month persistent HPV 18 infection, with a
pooled RR of 0.24 (95% CI: 0.14-0.42) for ITT cohorts
(2 RCTs, 12,948 participants) and a RR of 0.05 (95% CI:
0.03-0.09) for PPP cohorts (2 RCTs, 14,008), equivalent
to a 76% and 95% protection derived from vaccination,
respectively.
7) CIN2+ and Persistent Infection of ≥6 Months Associated
with HPV 31/33/45/52/58 (Figure 5, 6)
In ITT analyses, vaccines demonstrated statistically sig-
nificant reduction (p = 0.003) in the risk of CIN2+ asso-
ciated with non-vaccine oncogenic HPV types with a
Figure 4 Vaccine efficacy against persistent infection of ≥ 6-months with HPV 16 and 18
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Page 9 of 16pooled RR (3 RCTs, 34,476 participants) of 0.79 (95%
CI: 0.67-0.92) (Figure 5A). However, there was border-
line significant heterogeneity among included trials
(Cochrane’s Q, p = 0.05; I
2 = 74%). The overall RR was
0.58 (95% CI: 0.43-0.77) for PPP cohorts (3 RCTs,
25,011 participants), indicating a ~40% cross-protection
against non-vaccine oncogenic HPV-associated CIN2+.
Two RCTs demonstrated comparable level of protec-
tion against 6-month persistent HPV 31/33/45/52/58
infection in ITT and PPP cohorts, respectively (Figure
5B). The pooled RR was 0.77 (95% CI: 0.72-0.85) for
ITT cohorts (20,524 participants) and 0.72 (95% CI:
0.65-0.79) for PPP cohorts (17,372 participants) indicat-
ing a limited but statistically significant cross-protection.
Figure 5 Cross-protection against infections and diseases associated with non-vaccine oncogenic HPV types
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Page 10 of 16When cross-protection against 6-month persistent
infection was examined by HPV type (Figure 6A-E),
prophylactic vaccines were most efficacious in prevent-
ing persistent HPV 31 infection (RR: ITT 0.47 and PPP
0.30), followed by persistent infection with HPV 45
(RR: ITT 0.50 and PPP 0.42) and HPV 33 (RR: ITT
0.65 and PPP 0.57). No statistically significant cross-
protection against persistent infection with HPV 52 or
58 was detected in individual trials or overall. Signifi-
cant heterogeneity between included trials was
observed in both ITT and PPP analyses of vaccine effi-
cacy against persistent HPV 45 infections (ITT:
Cochrane’sQ ,p<0 . 0 0 0 1 ,I
2 = 94%; PPP: Cochrane’s
Q, p < 0.0003, I
2 = 93%).
IV. Assessment of Adverse Events (Figure 7)
Adverse events (AEs) were monitored by the use of daily
vaccination report cards within 15 or 30 days of injec-
tion, as well as solicitation throughout the study. Occur-
rence of AEs was reported in all RCTs. Pain at injection
site was the most frequently reported AE ranging from
83.0 - 93.4% in vaccine groups and 75.4 - 87.2% in control
groups. Headache and fatigue were the most common vac-
cine-related systemic AEs observed in approximately
Figure 6 Cross-protection against persistent infection of ≥ 6-months with HPV 31, 33, 45, 52 and 58
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Page 11 of 1650-60% of all participants. Serious AE reported included
abnormal pregnancy outcomes, blood and lymphatic
system disorder, hepatobiliary disorder, immune system
disorder, cardiac and vascular disorder, gastrointestinal
disorder, musculoskeletal and connective tissue disorder,
nervous system disorder, psychiatric disorder, renal
and urinary disorder, reproductive system and breast
disorder, respiratory, thoracic and mediastinal disorder,
skin and subcutaneous tissue disorder, neoplasm, infection
and infestation, injury, poisoning and procedural
complications. The most commonly reported serious AEs
were abnormal pregnancy outcomes such as abnormal
infant and spontaneous abortion. The pooled RR for parti-
cipants experiencing one or more serious AEs was 1.00
(95% CI: 0.91-1.09) suggesting a statistically insignificant
difference in the risk of serious AEs between vaccine and
control groups (Figure 7A).
Serious AEs that were judged to be related to injection
included bronchospasm, gastroenteritis, headache,
hypertension, injection-site pain, decrease in joint move-
Figure 7 Assessment of Adverse Events
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Page 12 of 16ment at injection site, hypersensitivity to injection, chills,
headache and fever. Four of the seven trials reported
zero injection-related serious AEs (Figure 7B). Among
those reporting vaccine-related serious AEs, the event
rate ranged from 0-0.1%. Overall there was no statisti-
cally significant difference in the risk for vaccine-related
serious AEs between vaccine and control groups (RR,
1.82; 95% CI: 0.79-4.20).
V. Sensitivity Analyses (Additional file 2)
Sensitivity analysis was performed to identify potential
sources of heterogeneity that was observed in the ITT
analyses of CIN1+ and CIN2+ associated HPV 16. The
included trials did not differ by methodological qualities
in terms of allocation concealment, blinding, effect size,
power calculation, and participant withdraw and drop-
out. Therefore, heterogeneity was unlikely attributed to
the methodological quality. We further examined the
heterogeneity among included trials according to study
characteristics including study population, inclusion/
exclusion criteria, intervention, comparator, endpoints
chosen and efficacy populations defined, as well as parti-
cipant baseline characteristics such as age, HPV preva-
lence and lifetime number of sex partners. The pooled
efficacy estimates for FUTURE trials were significantly
lower than those for all other RCTs (CIN2+: FUTURE II
0.59, 95% CI: 0.44-0.78 vs. Other RCTs 0.11, 95% CI:
0.05-0.23; CIN1+: FUTURE I 0.55, 95% CI: 0.40-0.75 vs.
Other RCTs 0.15, 95% CI: 0.07-0.29). With the FUTURE
trials excluded, the observed heterogeneity dissipated for
either endpoint (CIN2+: I
2 = 59%, p = 0.09; CIN1+; I
2 =
0%, p = 0.70). The previously observed heterogeneity and
lower efficacy reported by the FUTURE trials was likely
due to inclusion of a larger proportion of trial partici-
pants already infected with vaccine HPV types at baseline
i nt h eI T Tc o h o r t s ,s o m eo fw h o mm a yh a v ep r o g r e s s e d
to cervical neoplasia during the follow-up period.
Discussion
In summary, the totality of evidence derived from this
meta-analysis demonstrated that prophylactic vaccines
are highly efficacious in preventing vaccine type HPV
infections and associated precancerous cervical lesions.
Efficacy against persistent HPV 16 and 18 infections was
most impressive, offering 95% efficacy for PPP and 75-
85% for ITT cohorts. Vaccines were equally efficacious
in preventing HPV 16 and 18 associated CIN1+ with an
efficacy of 57-78% for ITT and 97-98% for PPP cohorts.
Efficacy was also pronounced for CIN2+ associated with
HPV 16 and 18 with over 90% efficacy for PPP and 50%
for ITT cohorts.
Overall, a notable higher efficacy was observed in PPP
cohorts than in the ITT or MITT cohorts. The discre-
pancies are likely attributable to differences in the
populations evaluated and case counting methods
adopted for different types of efficacy analyses. The ITT
cohort typically included women who had received ≥1
dose of vaccine or placebo, and had available follow-up
data regardless of HPV status at enrollment. A MITT
cohort required participants to be virologically and sero-
logically naïve to vaccine HPV types at enrollment, in
addition to the requirements set for ITT. In some cases,
a normal cytology at enrollment and DNA negativity to
other oncogenic HPV types at enrollment were also
required. The PPP cohort was, in comparison, more
restricted and only included women who received all
three doses of vaccine or placebo, were naïve (DNA-
and sero-negative) to vaccine HPV types at enrollment
and remained DNA-negative through the regimen with
no protocol violation. In addition, case counting for ITT
or MITT analyses usually started on day 1, instead of
one month post dose three in most PPP analyses. The
excessive cases observed in ITT cohorts compared with
those in PPP cohorts were likely the results of incom-
plete vaccine regimen and the inclusion of prevalent
cases of HPV infection and low-grade cervical diseases
at enrollment.
The ITT cohort in the vaccine trials mimics young
w o m e ni nt h eg e n e r a lp o p u l a t i o nw h om a yh a v eb e e n
exposed to vaccine type HPV infection and have less
than perfect compliance with vaccination protocol,
whereas PPP cohorts approximates pre-sexually active
young adolescents naïve to vaccine type HPV with per-
fect or nearly perfect compliance. The young adolescent
group becomes susceptible soon after their initiation of
sexual activities, even if they are not engaged in penetra-
tive sexual intercourse [19,20]. The notable difference in
prophylactic efficacy against infection and cervical dis-
eases between the ITT and PPP cohorts of young
females and the lack of therapeutic efficacy [21] high-
light the public health importance of early vaccination
of adolescent girls prior to their sexual debut and vac-
cine compliance.
While sexually naïve young women may derive
greater public health benefit from HPV vaccination,
vaccine appears to be of benefit to a broad age range
of women many of whom may have acquired transient
infections in the past or had active infection at the
time of vaccination. Preliminary data from the quadri-
valent vaccine trial of Muñoz and associates [18]
enrolling 3819 24-45 year old women showed a 90%
efficacy against combined incidence of vaccine HPV-
related 6-month persistent infection, CIN 1-3 or exter-
nal genital warts in PPP cohorts and a 31% efficacy in
the ITT cohort. Recent studies further demonstrated
that even among women who had detectable serologi-
cal evidence of vaccine-HPV infection in the past and
no DNA evidence of active infection at enrollment,
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protection (95% CI: <0-100) against CIN2+ associated
with a vaccine HPV type with which the women had
been previously infected [22]. These data suggest that
older reproductive-age women can still benefit from
prophylactic vaccination.
Whether prophylactic vaccines offer long-term protec-
tion remains an important unanswered question. Two
included trials offered an extended follow-up of 53
months and 60 months [9,23] and both reported high
sustained efficacy against vaccine HPV infection and
associated cervical diseases for the extended follow-up
phase. The longest follow-up available to date is 8.5
years for the monovalent vaccine trial [24]. The trial
reports an efficacy against HPV 16-related CIN2+ of
64% (95% CI: -51-94) for ITT and 100% (95% CI: 29-
100) for PPP in the extended follow-up phase among a
subset (n = 280) of participants enrolled for the initial
trial, comparable with the efficacy of 78% (95% CI: 41-
93) for ITT and 100% (95% CI: 65-100) for PPP
reported in the initial trial. Future efficacy data from
longer-term follow-up of bivalent and quadrivalent vac-
cine trials are critical to fully address long-term efficacy.
Our results demonstrated statistically significant but
limited protection against CIN2+ associated with non-
vaccine-type oncogenic HPV that are phylogenetically
related to HPV 16 and 18 in both ITT and PPP cohorts
(RR: 0.79 in ITT and 0.58 in PPP). Limited cross-protec-
tion against persistent infection of ≥6 months was con-
sistently observed for HPV 31, and to a lesser extent
against persistent HPV 45 and HPV 33 infection. No
statistically significant protection was detected against
persistent infection with HPV 52 and 58. The added
benefit of cross-protection may result in further reduc-
tions in incidence of cervical cancer and precancerous
lesions following vaccination. However, whether cross-
protection remains present in long-term follow-up, and
if present, how the efficacy trend for non-vaccine types
compares with that of vaccine HPV types has yet to be
determined.
Results of the safety assessment indicated that injec-
tion-related local and systemic symptoms were generally
mild. The most commonly reported serious AEs were
abnormal pregnancy outcomes. Serious AEs that were
considered to be vaccine-related were rare. It was noted
that data on abnormal pregnancy outcomes were under-
reported, only available in three of the seven trials
included [16,17,25]. The currently licensed prophylactic
vaccines evaluated in the review were not recommended
by the Advisory Committee on Immunization Practices
(ACIP) for pregnant women, although it was suggested
that abnormal pregnancy outcomes did not differ signifi-
cantly between vaccine and control group, and were
comparable with those reported in surveillance registries
and the literature in a recent publication that combined
pregnancy and infant outcomes from five Phase III
RCTs [26]. However, pregnancy testing was not required
before vaccination by ACIP. Given the high frequency of
pregnancy among 15-44 year-old women in the general
population (103.2 per 1,000 women) [27] as well as in
vaccine trial participants (~20%) [16,26], further data on
pregnancy outcomes, and long-term follow-up of live
births conceived during trial regimen are needed for a
full assessment of vaccine safety and to facilitate women
with an informed vaccine decision.
There are several limitations to the evidence presented
here. We were not able to evaluate prophylactic efficacy
against anogenital warts, vulvar or vaginal diseases asso-
ciated with vaccine HPV due to the common use of
composite endpoints in individual RCTs that combined
infections, lesions and cancers of various anogenital
sites, and were often incomparable across RCTs
[17,18,23]. In addition, we did not evaluate HPV 6 or
11-specific efficacy given that VLP components of HPV
6 and 11 were only included in the quadrivalent vaccine
from Merck. Furthermore, we recognize that the pooled
efficacy results presented here were derived from sus-
ceptible young females with limited sexual exposure to
HPV, therefore, they may not be applicable to more
mature, sexually active female populations. Lastly, due
to the limited number of published trials available to
date, we were not able to assess efficacy pertaining to
each type of vaccine.
Conclusion
In conclusion, our review demonstrated that VLP-based
prophylactic HPV vaccines are highly efficacious in pre-
venting persistent infection and cervical diseases asso-
ciated with vaccine HPV types among young female
adults. The vaccines were safe and generally well toler-
ated. Vaccination of adolescent girls prior to sexual
debut appeared to be the most effective public health
measure for prevention of cervical diseases and cancer.
Questions related to long-term efficacy and safety have
yet to be addressed.
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